



---

**Professor Andrew Cuthbertson AO**  
**Chief Scientific Officer**  
CSL Limited

After completing medical training at the University of Melbourne and PhD in Immunology at the Walter and Eliza Hall Institute in Australia, Professor Cuthbertson spent five years doing molecular biology research as a staff member at the Howard Florey Institute in Melbourne and the National Institutes of Health in the United States. He then spent seven years at Genentech Inc in San Francisco, working on anti-VEGF therapy for age related macular degeneration.

In 2016 he was made an Enterprise Professor, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne and an Officer of the Order of Australia for his services to medical research.

Professor Cuthbertson, the Chief Scientific Officer, was recruited to CSL in 1997 and in 2018 was appointed as an Executive Director on the CSL Limited Board.



---

**William Campbell**  
**Executive Vice President & Chief Commercial Officer**  
CSL Limited, King of Prussia, Pennsylvania

Bill was appointed as Executive Vice President & Chief Commercial Officer on July 1, 2017. Bill has responsibility for a variety of global functions including Sales, Marketing, Commercial Development, Medical Affairs, Analytics and Public Policy. Bill is accountable for our global Commercial strategy and leads a team of 1,700 Commercial professionals around the world.

Prior to being appointed to his current role, Bill led CSL Behring's North American Commercial Operations. Bill and his team were responsible for the successful launches of IDELVION, AFSTYLA and HAEGARDA and other new products. Under Bill's leadership, the North American region delivered substantial revenue and volume growth across the portfolio.

Bill has more than 35 years of diverse Pharmaceutical and Biotechnology experience across a range of therapeutic areas, including Oncology, Women's Health, Vaccines, and Plasma Proteins. He has served in a number of progressive senior leadership roles with Wyeth, Abbott, Teva, Cephalon and Centeon, a CSL predecessor company.

Bill is currently a member of the Board of Directors of the Biotechnology Innovation Organization (BIO) and previously was a member of the North American Board of Directors for the Plasma Protein Therapeutics Association.



---

**Bill Mezzanotte**  
**Executive Vice President, Research and Development**  
CSL Behring

Bill Mezzanotte is responsible for developing and executing CSL's Research & Development strategy and portfolio, including the identification and development of all R&D platforms, skills and expertise necessary for success.

In April 2017, Bill joined the company as Head of Clinical Development, responsible for clinical science, statistics and clinical operations across CSL Behring's portfolio. Most recently he served as Senior Vice President and Head of Development, where he oversaw regulatory, project management, clinical science & operations, plasma, recombinant protein and gene therapy pharmaceutical development activities worldwide.

Prior to CSL, he was Senior Vice President and Therapeutic Area Head, Respiratory for Boehringer Ingelheim and spent 16 years with AstraZeneca in research and development, assuming roles of increasing leadership and management responsibility across multiple therapeutic areas.

Bill holds an undergraduate degree from Villanova University, obtained his M.D. at the University of Pennsylvania and a Master of Public Health degree from Johns Hopkins University.

Bill is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine.



---

**Andrew Nash**  
**Senior Vice President Research**  
CSL Limited

Andrew Nash completed his PhD in immunology at The University of Melbourne in 1988 and, after moving to the Centre for Animal Biotechnology in the Faculty of Veterinary Science, developed and led a research group focused on basic and applied aspects of cytokine biology.

In 1996 he joined the ASX listed biotechnology company Zenyth Therapeutics (then Amrad Corporation) as a senior scientist and subsequently held a number of positions including Director of Biologicals Research and Chief Scientific Officer. In July of 2005 he was appointed Chief Executive Officer of Zenyth, a position which he held up until the acquisition of Zenyth by CSL Limited in November 2006. Following the acquisition he was appointed as CSL's SVP, Research and is currently based at the Bio21 Institute where he leads a large global effort focused on the discovery and development of new protein, cell and gene-based medicines to treat serious human disease.



## BIOGRAPHY



### **GREGG SYLVESTER MD, MPH** *VICE PRESIDENT, MEDICAL AFFAIRS*

---

Gregg is the Vice President of Medical Affairs for Seqirus, a CSL company. He is responsible for leading the medical and scientific strategy for Seqirus' portfolio of products.

As a physician with expertise in pediatrics, epidemiology and public policy, he has spent his career preventing and treating diseases. He completed his medical training at Johns Hopkins School of Hygiene and Public Health. He worked in the U.S. Senate as a Joseph P. Kennedy, Jr. Public Policy Fellow and has held important positions including; Pediatric Lead for Prevnar 13 at Pfizer, Inc., Medical Affairs Lead for Gardasil at Merck & Co., Inc., as well as the Secretary of Health & Social Services for the state of Delaware.

Gregg served his country as a Commissioned Officer in the elite core of epidemiologists, known as the Epidemic Intelligence Service, and received the Order of the First State in recognition for his outstanding service to the citizens of Delaware.